• Eser Kirkizlar, Nicoleta Serban, Jennifer A Sisson, Julie L Swann, Claire S Barnes, and Michael D Williams.
• Natera, Inc., San Carlos, California.
• Ophthalmology. 2013 Dec 1; 120 (12): 2604-2610.

ObjectiveTo explore the cost-effectiveness of telemedicine for the screening of diabetic retinopathy (DR) and identify changes within the demographics of a patient population after telemedicine implementation.DesignA retrospective medical chart review (cohort study) was conducted.ParticipantsA total of 900 type 1 and type 2 diabetic patients enrolled in a medical system with a telemedicine screening program for DR.MethodsThe cost-effectiveness of the DR telemedicine program was determined by using a finite-horizon, discrete time, discounted Markov decision process model populated by parameters and testing frequency obtained from patient records. The model estimated the progression of DR and determined average quality-adjusted life years (QALYs) saved and average additional cost incurred by the telemedicine screening program.Main Outcome MeasuresDiabetic retinopathy, macular edema, blindness, and associated QALYs.ResultsThe results indicate that telemedicine screening is cost-effective for DR under most conditions. On average, it is cost-effective for patient populations of >3500, patients aged <80 years, and all racial groups. Observable trends were identified in the screening population since the implementation of telemedicine screening: the number of known DR cases has increased, the overall age of patients receiving screenings has decreased, the percentage of nonwhites receiving screenings has increased, the average number of miles traveled by a patient to receive a screening has decreased, and the teleretinal screening participation is increasing.ConclusionsThe current teleretinal screening program is effective in terms of being cost-effective and increasing population reach. Future screening policies should give consideration to the age of patients receiving screenings and the system's patient pool size because our results indicate it is not cost-effective to screen patients aged older than 80 years or in populations with <3500 patients.Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…